Wagstaff, J., Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Rutkowski, P., . . . Wolchok, J. D. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The Lancet Oncology, 19(11), pp. 1480-1492. doi:10.1016/S1470-2045(18)30700-9

Wagstaff, John, et al. "Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab Alone in Advanced Melanoma (CheckMate 067): 4-year Outcomes of a Multicentre, Randomised, Phase 3 Trial." The Lancet Oncology 19, no. 11 (2018): 1480-1492.

Wagstaff, John, et al. "Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab Alone in Advanced Melanoma (CheckMate 067): 4-year Outcomes of a Multicentre, Randomised, Phase 3 Trial." The Lancet Oncology 19.11 (2018): 1480-1492.